---
figid: PMC4174763__fcimb-04-00138-g0001
figtitle: Fungal and mammal GSLs biosynthetic pathways and potential targets for new
  antifungal therapies
organisms:
- Saccharomyces cerevisiae
- Candida albicans
- Aspergillus fumigatus
- Aspergillus nidulans
- Eucalyptus intertexta
- Aspergillus niger
- Cryptococcus neoformans
- Histoplasma capsulatum
- Paracoccidioides brasiliensis
- Sporothrix schenckii
- Opsanus beta
- Boa constrictor
- Homo sapiens
- Mus musculus
organisms_ner:
- Drosophila melanogaster
pmcid: PMC4174763
filename: fcimb-04-00138-g0001.jpg
figlink: /pmc/articles/PMC4174763/figure/F1/
number: F1
caption: Fungal and mammal GSLs biosynthetic pathways and potential targets for new
  antifungal therapies. The scheme displays the biosynthetic pathways of fungal GIPCs
  (left), fungal GlcCer (center), and mammalian GSLs (right). The red arrows indicates
  the biosynthetic step where the inhibition by AbA and P4/analogs occurs, the red
  dashed boxes in the glycosphingolipid biosynthetic pathway indicate potential targets
  for the development of new antifungal therapies. LCB, long chain base; FA, fatty
  acid; IPC, inositol phosphorylceramide; MIPC, mannosylinositol phosphorylceramide;
  GIPC, glycosylinositol phosphorylceramide; AbA, Aureobasidin A; P4, D-threo-1-phenyl-2-palmitoyl-3-pyrrolidinopropanol.
papertitle: Structural diversity and biological significance of glycosphingolipids
  in pathogenic and opportunistic fungi.
reftext: Luciana L. Guimar√£es, et al. Front Cell Infect Microbiol. 2014;4:138.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.6282789
figid_alias: PMC4174763__F1
figtype: Figure
redirect_from: /figures/PMC4174763__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4174763__fcimb-04-00138-g0001.html
  '@type': Dataset
  description: Fungal and mammal GSLs biosynthetic pathways and potential targets
    for new antifungal therapies. The scheme displays the biosynthetic pathways of
    fungal GIPCs (left), fungal GlcCer (center), and mammalian GSLs (right). The red
    arrows indicates the biosynthetic step where the inhibition by AbA and P4/analogs
    occurs, the red dashed boxes in the glycosphingolipid biosynthetic pathway indicate
    potential targets for the development of new antifungal therapies. LCB, long chain
    base; FA, fatty acid; IPC, inositol phosphorylceramide; MIPC, mannosylinositol
    phosphorylceramide; GIPC, glycosylinositol phosphorylceramide; AbA, Aureobasidin
    A; P4, D-threo-1-phenyl-2-palmitoyl-3-pyrrolidinopropanol.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Hydr2
  - l(1)1Ef
  - l(3)C18
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Dihydrosphingosine
  - 2-OH
  - C18 fatty acyl-CoA
  - fatty acyl-CoA
  - Ceramide
  - Glucosylceramide
---
